Home/Browse by collection/Clinical/Translational Cancer Immunotherapy

Clinical/Translational Cancer Immunotherapy

Section Edited by Jason J. Luke, MD, FACP and Douglas G. McNeel, MD, PhD Clinical trials: prospective studies including first-in-man clinical trials, phase II/III clinical studies, and immune monitoring investigations. Small, single institution-based retrospective reports are discouraged. Preclinical studies: studies that lead to mechanistic understanding or novel development of agents and combination therapies directly relevant to human immunotherapy.

Showing results 21 - 30 of 100

Sorted by most recent

A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer
Pénélope Desroys du Roure, Laurie Lajoie, Aude Mallavialle, Lindsay B Alcaraz, Hanane Mansouri, Lise Fenou, Véronique Garambois, Lucie Rubio, Timothée David, Loïs Coenon, Florence Boissière-Michot, Marie-Christine Chateau, Giang Ngo, Marta Jarlier, Martin VillalbaSee the full list of authors

30 January 2024